SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories trades jubilantly on the BSE

06 Jul 2021 Evaluate

Morepen Laboratories is currently trading at Rs. 73.90, up by 8.85 points or 13.60% from its previous closing of Rs. 65.05 on the BSE.

The scrip opened at Rs. 65.40 and has touched a high and low of Rs. 75.00 and Rs. 65.40 respectively. So far 2224348 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 72.40 on 15-Jun-2021 and a 52 week low of Rs. 19.30 on 28-Jul-2020.

Last one week high and low of the scrip stood at Rs. 75.00 and Rs. 62.60 respectively. The current market cap of the company is Rs. 3348.96 crore.

The promoters holding in the company stood at 34.54%, while Institutions and Non-Institutions held 3.57% and 61.89% respectively.

Morepen Laboratories and The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) have declared the production of the test batch of the Russian Sputnik V coronavirus vaccine in an exclusive facility in state of Himachal Pradesh (HP).

The first batch will be shipped to the Gamaleya Center for the quality control. RDIF and Morepen Laboratories signed a cooperation agreement in June 2021 and are actively implementing the technology transfer.

Morepen Laboratories is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

Morepen Laboratories Share Price

41.35 -0.57 (-1.36%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×